Our Story
The new virtual biosimilar company, Polpharma Biologics, located in Swizterland, was born from a strategic transformation — building on the proven legacy of a leading biosimilar company, while embracing the agility of a new, focused company. Backed by deep expertise, strong infrastructure, and a global network, we are now positioned to move faster, partner smarter, and shape the next era of biosimilar innovation.
Polpharma Biologics Growth Timeline
1935
Polpharma established.
2000
Acquisition of Polpharma by Jerzy Starak , a committed and visionary entrepreneur who still controls Polpharma and Polpharma Biologics today.
2010
Polpharma, a leading pharmaceutical company in Poland and the central European region, launches biotech operations.
2013
Biotechnology R&D centre established in Gdańsk.
2014
Bioeq established – joint venture with Atos on the co-development of Ranibizumab.
2016
Acquisition of Bioceros BV, an early stage biotech development company in Utrecht, the Netherlands.
2018
Rapid development of the biotechnology R&D centre in Gdańsk.
2019
Creation of an independent Polpharma Biologics (spin-off from Polpharma). Out-licensing deal for Natalizumab with Sandoz. Out-licensing deal for Ranibizumab with Coherus.
2020
Duchnice manufacturing and development site joins Polpharma Biologics.
2021
2021 Bioeq, a joint venture of Polpharma Biologics Group, enters into an agreement with Teva to commercialize a biosimilar drug to Ranibizumab in Europe and Canada